Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $610,567 | $370,662 | $381,170 | $426,371 |
| - Cash | $208,343 | $69,429 | $78,530 | $224,254 |
| + Debt | $40,168 | $41,131 | $41,864 | $42,715 |
| Enterprise Value | $442,392 | $342,364 | $344,504 | $244,832 |
| Revenue | $12,768 | $23,194 | $84,929 | $60,647 |
| % Growth | -45% | -72.7% | 40% | – |
| Gross Profit | $10,673 | $23,194 | $84,929 | $60,647 |
| % Margin | 83.6% | 100% | 100% | 100% |
| EBITDA | -$28,163 | -$13,429 | $46,084 | $15,065 |
| % Margin | -220.6% | -57.9% | 54.3% | 24.8% |
| Net Income | -$27,081 | -$12,295 | $46,885 | $13,437 |
| % Margin | -212.1% | -53% | 55.2% | 22.2% |
| EPS Diluted | -0.33 | -0.15 | 0.57 | 0.22 |
| % Growth | -120% | -126.3% | 159.1% | – |
| Operating Cash Flow | $100,428 | -$34,720 | -$45,492 | $128,922 |
| Capital Expenditures | -$651 | -$1,695 | -$1,587 | -$183 |
| Free Cash Flow | $99,777 | -$36,415 | -$47,079 | $128,739 |